EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS

The purpose of the study was to analyze the ability of five antitumor drugs from the pharmaceutical group of protein kinase inhibitors (gefitinib, imatinib, pazopanib, ponatinib and enzastaurin) to reactivate the expression of the epigenetically silenced GFP in HeLa TI cells, and to estimate the eff...

Full description

Bibliographic Details
Main Authors: V. P. Maksimova, J. V. Makus, O. G. Usalka, E. S. Lylova, P. E. Bugaeva, E. M. Zhidkova, D. A. Fedorov, O. P. Lizogub, E. A. Lesovaya, G. A. Belitsky, M. G. Yakubovskaya, K. I. Kirsanov
Format: Article
Language:Russian
Published: Tomsk National Research Medical Center of the Russian Academy of Sciences 2020-09-01
Series:Sibirskij Onkologičeskij Žurnal
Subjects:
hat
Online Access:https://www.siboncoj.ru/jour/article/view/1531
id doaj-5e44a769e15146daaabde60bf96de8c6
record_format Article
spelling doaj-5e44a769e15146daaabde60bf96de8c62021-07-28T21:02:07ZrusTomsk National Research Medical Center of the Russian Academy of SciencesSibirskij Onkologičeskij Žurnal1814-48612312-31682020-09-01194677810.21294/1814-4861-2020-19-4-67-78768EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORSV. P. Maksimova0J. V. Makus1O. G. Usalka2E. S. Lylova3P. E. Bugaeva4E. M. Zhidkova5D. A. Fedorov6O. P. Lizogub7E. A. Lesovaya8G. A. Belitsky9M. G. Yakubovskaya10K. I. Kirsanov11N.N. Blokhin National Medical Research Center of OncologyMIREA – Russian Technological UniversityI.M. Sechenov First Moscow State Medical University (Sechenov University)N.N. Blokhin National Medical Research Center of OncologyI.M. Sechenov First Moscow State Medical University (Sechenov University)N.N. Blokhin National Medical Research Center of OncologyI.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)N.N. Blokhin National Medical Research Center of Oncology; I.P. Pavlov Ryazan State Medical UniversityN.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of Oncology; RUDN UniversityThe purpose of the study was to analyze the ability of five antitumor drugs from the pharmaceutical group of protein kinase inhibitors (gefitinib, imatinib, pazopanib, ponatinib and enzastaurin) to reactivate the expression of the epigenetically silenced GFP in HeLa TI cells, and to estimate the effect of epigenetically active drugs on: 1) acetylation and methylation of histones H3 and H4; 2) integral DNA methylation; 3) activity of HAT and HDAC1 enzymes; 4) expression levels of the genes encoding epigenetic regulation enzymes (DNMT1, DNMT3A, DNMT3B; SIRT1, HDAC1; SETD1A, SETD1B, SUV420H1, SUV420H2, SUV39H1, SUV39H2). Material and Methods. The epigenetic activity of antitumor drugs was determined using the HeLa TI test system, a population of HeLa cells with the retroviral vector containing the epigenetically silenced GFP. The level of integral DNA methylation was analyzed using MspI/HpaII methyl-sensitive restriction analysis. Histone modifications were analyzed by Western blotting with antibodies to acetylated and methylated histones H3 and H4. The total activity of HAT enzymes was analyzed using Histone Acetyltransferase Activity Assay Kit. Expression of the epigenetic enzyme genes was analyzed using real-time quantitative RT-PCR. Results. It was shown that only the enzyme inhibitor Cβ protein kinase enzastaurin had the ability to reactivate the expression of epigenetically silenced GFP in the HeLa TI cells. We showed that under the action of enzastaurin, the level of integral DNA methylation and expression of DNMT3A and DNMT3B DNA methyltransferase genes decreased. It was also found that enzastaurin reduced the expression levels of histone deacetylases HDAC1 and SIRT1, but did not affect the activity and expression levels of histone acetylases, the level of histone methylation (H3K4me3, H3K9me3, H3K27me3, H4K20me3), and the level of expression of the histone methyltransferases (SUV39H1, SUV39H2, SUV420H1, SUV420H2, SETD1A и SETD1B). Conclusion. The data obtained are important for clarifying the mechanisms of action of 5 protein kinase inhibitors, in particular with respect to enzastaurin, the protein kinase Cβ inhibitor, for which the ability to reactivate epigenetically silent genes due to the effect on DNA methylation and histone acetylation was demonstrated.https://www.siboncoj.ru/jour/article/view/1531protein kinase inhibitorsenzastaurinepigenetic activityhela tihistone modificationsdna methylationhathdac
collection DOAJ
language Russian
format Article
sources DOAJ
author V. P. Maksimova
J. V. Makus
O. G. Usalka
E. S. Lylova
P. E. Bugaeva
E. M. Zhidkova
D. A. Fedorov
O. P. Lizogub
E. A. Lesovaya
G. A. Belitsky
M. G. Yakubovskaya
K. I. Kirsanov
spellingShingle V. P. Maksimova
J. V. Makus
O. G. Usalka
E. S. Lylova
P. E. Bugaeva
E. M. Zhidkova
D. A. Fedorov
O. P. Lizogub
E. A. Lesovaya
G. A. Belitsky
M. G. Yakubovskaya
K. I. Kirsanov
EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS
Sibirskij Onkologičeskij Žurnal
protein kinase inhibitors
enzastaurin
epigenetic activity
hela ti
histone modifications
dna methylation
hat
hdac
author_facet V. P. Maksimova
J. V. Makus
O. G. Usalka
E. S. Lylova
P. E. Bugaeva
E. M. Zhidkova
D. A. Fedorov
O. P. Lizogub
E. A. Lesovaya
G. A. Belitsky
M. G. Yakubovskaya
K. I. Kirsanov
author_sort V. P. Maksimova
title EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS
title_short EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS
title_full EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS
title_fullStr EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS
title_full_unstemmed EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS
title_sort epigenetic effects of enzastaurin – a new aspect in the mechanism of action of an anticancer drug from protein kinase inhibitors
publisher Tomsk National Research Medical Center of the Russian Academy of Sciences
series Sibirskij Onkologičeskij Žurnal
issn 1814-4861
2312-3168
publishDate 2020-09-01
description The purpose of the study was to analyze the ability of five antitumor drugs from the pharmaceutical group of protein kinase inhibitors (gefitinib, imatinib, pazopanib, ponatinib and enzastaurin) to reactivate the expression of the epigenetically silenced GFP in HeLa TI cells, and to estimate the effect of epigenetically active drugs on: 1) acetylation and methylation of histones H3 and H4; 2) integral DNA methylation; 3) activity of HAT and HDAC1 enzymes; 4) expression levels of the genes encoding epigenetic regulation enzymes (DNMT1, DNMT3A, DNMT3B; SIRT1, HDAC1; SETD1A, SETD1B, SUV420H1, SUV420H2, SUV39H1, SUV39H2). Material and Methods. The epigenetic activity of antitumor drugs was determined using the HeLa TI test system, a population of HeLa cells with the retroviral vector containing the epigenetically silenced GFP. The level of integral DNA methylation was analyzed using MspI/HpaII methyl-sensitive restriction analysis. Histone modifications were analyzed by Western blotting with antibodies to acetylated and methylated histones H3 and H4. The total activity of HAT enzymes was analyzed using Histone Acetyltransferase Activity Assay Kit. Expression of the epigenetic enzyme genes was analyzed using real-time quantitative RT-PCR. Results. It was shown that only the enzyme inhibitor Cβ protein kinase enzastaurin had the ability to reactivate the expression of epigenetically silenced GFP in the HeLa TI cells. We showed that under the action of enzastaurin, the level of integral DNA methylation and expression of DNMT3A and DNMT3B DNA methyltransferase genes decreased. It was also found that enzastaurin reduced the expression levels of histone deacetylases HDAC1 and SIRT1, but did not affect the activity and expression levels of histone acetylases, the level of histone methylation (H3K4me3, H3K9me3, H3K27me3, H4K20me3), and the level of expression of the histone methyltransferases (SUV39H1, SUV39H2, SUV420H1, SUV420H2, SETD1A и SETD1B). Conclusion. The data obtained are important for clarifying the mechanisms of action of 5 protein kinase inhibitors, in particular with respect to enzastaurin, the protein kinase Cβ inhibitor, for which the ability to reactivate epigenetically silent genes due to the effect on DNA methylation and histone acetylation was demonstrated.
topic protein kinase inhibitors
enzastaurin
epigenetic activity
hela ti
histone modifications
dna methylation
hat
hdac
url https://www.siboncoj.ru/jour/article/view/1531
work_keys_str_mv AT vpmaksimova epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT jvmakus epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT ogusalka epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT eslylova epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT pebugaeva epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT emzhidkova epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT dafedorov epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT oplizogub epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT ealesovaya epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT gabelitsky epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT mgyakubovskaya epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
AT kikirsanov epigeneticeffectsofenzastaurinanewaspectinthemechanismofactionofananticancerdrugfromproteinkinaseinhibitors
_version_ 1721263222915334144